| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
365,900,000 |
| Market
Cap: |
16.54(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.85 - $44.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,149,622 |
1,149,622 |
1,183,122 |
1,183,122 |
| Total Sell Value |
$45,675,983 |
$45,675,983 |
$46,889,732 |
$46,889,732 |
| Total People Sold |
3 |
3 |
4 |
4 |
| Total Sell Transactions |
25 |
25 |
26 |
26 |
| End Date |
2025-11-16 |
2025-08-15 |
2025-02-14 |
2024-02-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Urist Marshall |
EVP, Research & Investments |
• – – |
2026-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
19,970 |
27,368 |
|
- |
|
| Hite Christopher |
EVP & Vice Chairman |
• – – |
2026-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
26,626 |
685,136 |
|
- |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2026-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
26,626 |
49,511 |
|
- |
|
| Legorreta Pablo G. |
CEO, Chairman of the Board |
• • – |
2026-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
157,828 |
1,098,783 |
|
- |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2026-02-04 |
4 |
AS |
$43.29 |
$872,913 |
I/I |
(20,163) |
22,885 |
|
2% |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2026-02-03 |
4 |
AS |
$42.84 |
$4,924,997 |
I/I |
(114,954) |
23,972 |
|
4% |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2026-02-02 |
4 |
AS |
$42.08 |
$4,562,905 |
I/I |
(108,424) |
30,167 |
|
5% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2026-01-30 |
4 |
AS |
$41.09 |
$821,810 |
I/I |
(20,000) |
0 |
|
7% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2026-01-23 |
4 |
AS |
$40.26 |
$805,110 |
I/I |
(20,000) |
20,000 |
|
11% |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2026-01-20 |
4 |
AS |
$39.35 |
$2,737,940 |
I/I |
(69,582) |
36,010 |
|
14% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2026-01-16 |
4 |
AS |
$39.52 |
$790,346 |
I/I |
(20,000) |
40,000 |
|
13% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2026-01-09 |
4 |
AS |
$40.78 |
$815,634 |
I/I |
(20,000) |
60,000 |
|
11% |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2026-01-02 |
4 |
AS |
$38.42 |
$2,673,041 |
I/I |
(69,582) |
39,760 |
|
15% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2026-01-02 |
4 |
AS |
$38.48 |
$769,650 |
I/I |
(20,000) |
80,000 |
|
15% |
|
| Bassler Bonnie L |
Director |
– • – |
2025-12-31 |
4 |
A |
$38.74 |
$37,463 |
D/D |
967 |
73,132 |
|
- |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-26 |
4 |
AS |
$39.32 |
$786,380 |
I/I |
(20,000) |
100,000 |
|
14% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-19 |
4 |
AS |
$38.38 |
$767,582 |
I/I |
(20,000) |
120,000 |
|
16% |
|
| Lloyd George W. |
EVP, Investments & CLO |
• – – |
2025-12-18 |
4 |
AS |
$38.50 |
$1,180,053 |
I/I |
(30,654) |
0 |
|
16% |
|
| Lloyd George W. |
EVP, Investments & CLO |
• – – |
2025-12-17 |
4 |
AS |
$38.57 |
$3,060,280 |
I/I |
(79,346) |
30,654 |
|
17% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-16 |
4 |
AS |
$38.32 |
$766,420 |
I/I |
(20,000) |
140,000 |
|
16% |
|
| Coyne Terrance P. |
EVP & CFO |
• – – |
2025-12-15 |
4 |
AS |
$38.36 |
$2,669,172 |
I/I |
(69,582) |
43,510 |
|
16% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-05 |
4 |
AS |
$39.15 |
$714,224 |
D/D |
(18,242) |
7,398 |
|
12% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-05 |
4 |
AS |
$39.15 |
$913,591 |
I/I |
(23,334) |
160,000 |
|
12% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-01 |
4 |
AS |
$39.90 |
$727,856 |
D/D |
(18,242) |
25,640 |
|
12% |
|
| Urist Marshall |
EVP, Research & Investments |
• – – |
2025-12-01 |
4 |
AS |
$39.93 |
$931,633 |
I/I |
(23,333) |
183,334 |
|
12% |
|
332 Records found
|
|
Page 1 of 14 |
|
|
0.39 (0.87%) 
